“Vaccine Partnering Terms and Agreements” Recently Published by MarketPublishers.com
17 Oct 2011 • by Natalie Aster
LONDON – The majority of deals entered into by healthcare companies are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of negotiated deals terms of a prospective partner provides critical insight into the negotiation process regarding expectations of what can be achieved during the negotiation of terms. While many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered.
New research report “Vaccine Partnering Terms and Agreements” prepared by CurrentPartnering is aimed at providing detailed understanding and unprecedented access to vaccine trends and structure of vaccine partnering deals and agreements entered into by the top healthcare companies from pole to pole, as well as explaining how and why companies enter these deals.
Report Scope:
- trends in vaccine dealmaking in the biopharma industry since 2007;
- analysis of vaccine deal structure;
- access to headline, upfront, milestone and royalty data;
- case studies of real-life vaccine deals;
- access to over 1,500 vaccine deal documents;
- leading vaccine deals by value since 2007;
- most active vaccine dealmakers since 2007;
- leading vaccine partnering resources.
Title: Vaccine Partnering Terms and Agreements
Published: October, 2011
Pages: 663>
Price: US$ 2,695
Report Contents:
EXECUTIVE SUMMARY
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN VACCINE DEALMAKING
2.1. Introduction
2.2. Companion vaccine over the years
2.3. Bigpharma vaccine dealmaking activity
2.4. Bigpharma not active in vaccines
2.5. Vaccine partnering by deal type
2.6. Vaccine partnering by disease type
2.7 Average deal terms for vaccine
2.7.1 Vaccine headline values
2.7.2 Vaccine upfront payments
2.7.3 Vaccine milestone payments
2.7.4 Vaccine royalty rates
CHAPTER 3 – LEADING VACCINE DEALS
3.1. Introduction
3.2. Top vaccine deals by value
3.3. Top vaccine deals involving bigpharma
CHAPTER 4 – BIGPHARMA VACCINE DEALS
4.1. Introduction
4.2. How to use bigpharma vaccine partnering deals
4.3. Bigpharma vaccine partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
…
To order the report or ask for free sample pages, please contact [email protected]
CONTACTS
The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
Analytics & News
